Get the Stockscreener App
2.678
3.67%
-0.102
Prelude Therapeutics Inc stock is traded at $2.678, with a volume of 474.71K.
It is down -3.67% in the last 24 hours and up +32.57% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$2.78
Open:
$2.79
24h Volume:
474.71K
Relative Volume:
1.08
Market Cap:
$168.79M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-1.5045
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
+20.09%
1M Performance:
+32.57%
6M Performance:
+115.97%
1Y Performance:
+207.50%
1-Day Range:
$2.60
$3.04
1-Week Range:
$2.06
$3.04
52-Week Range:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
2.685 | 174.77M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.80 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.38 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
829.66 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.60 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.48 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Quarterly Risk: Does Prelude Therapeutics Incorporated have consistent dividend growthJuly 2025 Earnings & Safe Capital Allocation Plans - baoquankhu1.vn
Guidance Update: Is Prelude Therapeutics Incorporated stock trending bullishTreasury Yields & Technical Entry and Exit Alerts - baoquankhu1.vn
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat
How Prelude Therapeutics’ deal with Incyte changed its course - Delaware Business Times
What’s the beta of Prelude Therapeutics Incorporated stock2025 AllTime Highs & AI Powered Market Entry Strategies - mfd.ru
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Is Prelude Therapeutics Incorporated a cyclical or defensive stock2025 Sector Review & High Accuracy Swing Entry Alerts - mfd.ru
Is Prelude Therapeutics Incorporated in a long term uptrendJuly 2025 Market Mood & Technical Buy Zone Confirmation - mfd.ru
Prelude Therapeutics (NASDAQ:PRLD) Trading Down 0.9%Should You Sell? - MarketBeat
Is Prelude Therapeutics Incorporated stock trending bullishWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Prelude Therapeutics Secures FDA Clearance for Key Drug Candidate - AD HOC NEWS
Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected - RTTNews
Take Profit: Does Prelude Therapeutics Incorporated have a sustainable dividendTrade Analysis Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Did PRLD Stock Surge 13% Today? - Stocktwits
Aug Wrap: Is ETRACS 2xMonthly Pay Leveraged Index ETN benefiting from interest rate changes2025 Market WrapUp & Weekly Stock Breakout Alerts - baoquankhu1.vn
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - GlobeNewswire
Why did PRLD stock surge 13% today? - MSN
Prelude’s JAK2 V617F inhibitor PRT-12396 gains IND clearance - BioWorld MedTech
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens - Investing.com Canada
FDA clears Prelude Therapeutics’ IND for JAK2 inhibitor in blood disorders - Investing.com Canada
Prelude Therapeutics (PRLD) Advances Blood Cancer Drug Trial wit - GuruFocus
Prelude Therapeutics Incorporated Receives FDA Clearance of Investigational New Drug Application for PRT12396 - marketscreener.com
Prelude Therapeutics stock surges after FDA clears IND for cancer drug By Investing.com - Investing.com South Africa
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate - Seeking Alpha
Prelude Therapeutics stock surges after FDA clears IND for cancer drug - Investing.com India
Prelude Therapeutics receives FDA clearance of investigational new drug application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor - marketscreener.com
Prelude Therapeutics (PRLD) Gains FDA Approval for Phase 1 Study of PRT12396 - GuruFocus
Prelude Therapeutics Wins FDA IND Clearance for PRT12396 - TipRanks
Prelude Therapeutics Inc FDA Clearance for PRT12396 Phase 1 Study - TradingView
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor - ChartMill
Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology - TipRanks
Hedge Fund Bets: Will Prelude Therapeutics Incorporated announce a stock splitJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
Retail investors in Prelude Therapeutics Incorporated (NASDAQ:PRLD) are its biggest bettors, and their bets paid off as stock gained 12% last week - Yahoo Finance
Aug Highlights: Does MAMO outperform in volatile markets2025 Support & Resistance & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Prelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Aug Reactions: Can Prelude Therapeutics Incorporated outperform under higher oil pricesQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Market Review: Is Prelude Therapeutics Incorporated a cyclical or defensive stockMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn
How Prelude Therapeutics Incorporated stock compares to industry benchmarksPortfolio Risk Report & Free Community Consensus Stock Picks - ulpravda.ru
How Prelude Therapeutics Incorporated stock responds to policy changesMarket Activity Recap & Fast Entry High Yield Stock Tips - ulpravda.ru
Prelude Therapeutics (NASDAQ:PRLD) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Prelude Therapeutics Inc Announces New Clinical Developments - TradingView — Track All Markets
Aug Sentiment: How Prelude Therapeutics Incorporated stock responds to policy changesWeekly Investment Summary & Real-Time Market Sentiment Alerts - Улправда
Will Prelude Therapeutics Incorporated stock reach all time highs in 2025Portfolio Update Report & Expert Verified Movement Alerts - Улправда
Will Prelude Therapeutics Incorporated stock benefit from AI adoptionJuly 2025 Rallies & Free Real-Time Market Sentiment Alerts - Улправда
Quarterly Trades: Is Prelude Therapeutics Incorporated stock positioned well for digital economyStop Loss & Free Daily Entry Point Trade Alerts - ulpravda.ru
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MSN
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December - MarketBeat
Bullish Prelude Therapeutics Insiders Rewarded As Their Investment Rises To US$2.75m - Sahm
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1%What's Next? - MarketBeat
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prelude Therapeutics Inc Stock (PRLD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
0.09%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):